CEO Frazier expects Merck to be player in hep C market, M&A this year

Eric Palmer

& Co.'s CEO Kenneth his company to be a in that lucrative hepatitis C again with the anticipated approval month of its hep C candidate. That, along with some M&A deals and growth in oncology should propel the world's fourth largest drugmaker forward for some time, he said week.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS